Drug Profile
Cyclobenzaprine extended release - Adare Pharmaceuticals
Alternative Names: Amrix; Bonelax; Bonelax ER; Cyclobenzaprine hydrochloride extended-release capsules; EUR-1002Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eurand
- Developer Adare Pharmaceuticals; Teva Pharmaceutical Industries
- Class Amines; Analgesics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Small molecules
- Mechanism of Action Adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Musculoskeletal pain; Spasm
Highest Development Phases
- Marketed Musculoskeletal pain; Spasm
- No development reported Migraine
Most Recent Events
- 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
- 16 Mar 2015 Cyclobenzaprine extended release - Aptalis is available for licensing in Asia as of 16 Mar 2015. http://www.aptalispharmaceuticaltechnologies.com
- 16 Mar 2015 No development reported - Phase-III for Migraine in USA (PO)